<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03825809</url>
  </required_header>
  <id_info>
    <org_study_id>1231914</org_study_id>
    <nct_id>NCT03825809</nct_id>
  </id_info>
  <brief_title>Nonopioid Analgesia After Labral Surgery</brief_title>
  <official_title>Traditional vs. Nonopioid Analgesia After Labral Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single blinded, standard of care controlled clinical trial. This&#xD;
      project aims to compare postoperative pain control in patients in two treatment arms of&#xD;
      rotator cuff repair: a treatment group given a nonopioid pain control regimen, and a standard&#xD;
      of care control group given standard opioid pain control regimen&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: This is a randomized, single blinded, standard of care-controlled clinical&#xD;
      trial. All adult patients over eighteen desiring rotator cuff repair will be eligible.&#xD;
      Nonnarcotic postoperative pain control regimen described below were chosen based on previous&#xD;
      studies in fracture care and joint arthroplasty.&#xD;
&#xD;
      Patients will be consented and recruited. Once participation has been determined and consent&#xD;
      obtained, the names of participating patients will be provided to the research pharmacy.&#xD;
      Patients will be randomized with a computer-generated table in 2 patient blocks by the&#xD;
      research pharmacy. Patients postoperative analgesia will be divided into one of the following&#xD;
      2 treatment arms: 1) A novel nonopioid pain protocol or 2) traditional narcotic pain&#xD;
      analgesia&#xD;
&#xD;
      Primary endpoints is reduction in pain as measured by VAS and PROMIS. The endpoints will be&#xD;
      collected at each post-operative day using a journal. Moreover, endpoints will be collected&#xD;
      at the patient's first post-operative appointment. These appointments are scheduled within&#xD;
      one-week of the index procedure.&#xD;
&#xD;
      Statistical Analysis: All continuous data will be analyzed using independent 2-group t tests&#xD;
      and reported as means Â± standard deviations. Categorical data will be compared between the 2&#xD;
      groups using chi-square tests and reported as counts and percentages. A preliminary test to&#xD;
      confirm the quality of variances will be conducted prior to utilizing the t test to confirm&#xD;
      the appropriate statistical analysis. Nonparametric equivalents Wilcoxon rank-sum and Fisher&#xD;
      exact tests will be used as needed for nonnormal distributions and low variable numbers,&#xD;
      respectively. A multivariable regression analysis was performed to assess for potential&#xD;
      confounding demographic variables.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Anticipated">May 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Levels</measure>
    <time_frame>10 days post-operatively</time_frame>
    <description>Patients recorded pain levels 3 times per day using Visual analog scales until study completion. Average daily pain was calculated for each patient. Higher values portend worse control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-Reported Outcomes Measurement Information System</measure>
    <time_frame>10 days post-operatively</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System Physical Interference (PROMIS PI) nightly until study completion. Average PROMIS PI values calculated nightly. A higher score indicates more pain interference.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Narcotic Use</condition>
  <arm_group>
    <arm_group_label>Post-Operative Non Opioid Pain Protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered a post-operative non-opioid pain protocol consisting of:&#xD;
Celecoxib Ketorolac Gabapentin Acetaminophen Diazepam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Operative Traditional Pain Protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen 5-325</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Post-Operative Non Opioid Pain Protocol</description>
    <arm_group_label>Post-Operative Non Opioid Pain Protocol</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocodone-Acetaminophen</intervention_name>
    <description>Traditionally used narcotic pain protocol</description>
    <arm_group_label>Post-Operative Traditional Pain Protocol</arm_group_label>
    <other_name>Norco</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Post-Operative Non Opioid Pain Protocol</description>
    <arm_group_label>Post-Operative Non Opioid Pain Protocol</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Post-Operative Non Opioid Pain Protocol</description>
    <arm_group_label>Post-Operative Non Opioid Pain Protocol</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Post-Operative Non Opioid Pain Protocol</description>
    <arm_group_label>Post-Operative Non Opioid Pain Protocol</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam</intervention_name>
    <description>Post-Operative Non Opioid Pain Protocol</description>
    <arm_group_label>Post-Operative Non Opioid Pain Protocol</arm_group_label>
    <other_name>Valium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  All adult patients over age 18 and scheduled for a primary or revision labral surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria will include patients with a medical history of known allergies or&#xD;
             intolerance to allergies or intolerance to Celebrex, Tylenol, Neurontin,&#xD;
             dexamethasone, tramadol, substantial alcohol or drug abuse, and pregnancy, history of&#xD;
             narcotics within 6 months of surgery, renal impairment, peptic ulcer disease, GI&#xD;
             bleeding. Secondary exclusion criterion is an intact rotator cuff&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toufic R Jildeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toufic R Jildeh, MD</last_name>
    <phone>517-230-8511</phone>
    <email>tjildeh1@hfhs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toufic R Jildeh, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 27, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Toufic R. Jildeh</investigator_full_name>
    <investigator_title>Resident Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Diazepam</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Per request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

